Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.59 |
| ▸ | HTT | P42858 | 2/20 | 0.59 |
| ▸ | SCD | O00767 | 1/20 | 0.57 |
| ▸ | MEN1 | O00255 | 2/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 3/20 | 0.53 |
| ▸ | TSHR | P16473 | 3/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.51 |
| ▸ | USP2 | O75604 | 2/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | ADAMTS5 | Q9UNA0 | 2/20 | 0.51 |
| ▸ | NAMPT | P43490 | 1/20 | 0.51 |
| ▸ | PARP14 | Q460N5 | 1/20 | 0.51 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19049592 | 0.85 | SMN1; SMN2 (0.58) | SMN1; SMN2HTTSCDMEN1KMT2A | |
| SCHEMBL10373948 | 0.84 | BPTF (0.54) | SMN1; SMN2HTTSCDMEN1KMT2A | |
| SCHEMBL20699709 | 0.84 | BPTF (0.54) | SMN1; SMN2HTTSCDMEN1KMT2A | |
| SCHEMBL5390221 | 0.82 | CA12 (0.46) | SMN1; SMN2HTTMEN1KMT2APOLB | |
| SCHEMBL14020487 | 0.81 | SMN1; SMN2 (0.54) | SMN1; SMN2HTTSCDMEN1KMT2A | |
| SCHEMBL19002650 | 0.81 | HTT (0.54) | SMN1; SMN2HTTSCDMEN1KMT2A | |
| SCHEMBL19002651 | 0.81 | ADAMTS5 (0.58) | SMN1; SMN2HTTMEN1KMT2APOLB | |
| SCHEMBL5399904 | 0.81 | DRD2 (0.56) | SMN1; SMN2HTTMEN1KMT2APOLB | |
| SCHEMBL1458090 | 0.81 | HTR1A (0.73) | SMN1; SMN2MEN1KMT2ATSHRRAB9A | |
| SCHEMBL3119833 | 0.81 | ADRA2C (0.59) | SMN1; SMN2HTTMEN1KMT2APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2234992-B1 | PIPERAZINE DERIVATIVES AND THEIR USE AS LEPTIN RECEPTOR MODULATORS | ASTRAZENECA AB (SE) | 2012-02-22 | — | — | EP | claimed |
| US-20230121721-A1 | MONOACYLGLYCEROL LIPASE INHIBITORS | STICHTING HET NEDERLANDS KANKER INST ANTONI VAN LEEUWENHOEK ZIEKENHUIS (NL) | 2023-04-20 | — | — | US | disclosed |
| EP-3875452-A1 | MONOACYLGLYCEROL LIPASE INHIBITORS | Stichting Het Nederlands Kanker Instituut- Antoni van Leeuwenhoek Ziekenhuis (NL) | 2021-09-08 | — | — | EP | disclosed |
| EP-3727380-A1 | PURINE INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA | Merck Sharp&Dohme Corp. (US) | 2020-10-28 | — | — | EP | disclosed |
| US-7230105-B2 | 9-aminoacridine derivatives and process for the preparation thereof | SAMJIN PHARMACEUTICAL CO., LTD. (KR) | 2007-06-12 | — | — | US | disclosed |
| CN-1280276-C | 9-aminoacridine derivatives and process for the preparation thereof | SAMJIN PHARM CO LTD (KR) | 2006-10-18 | — | — | CN | disclosed |
| US-20050222167-A1 | 9-aminoacridine derivatives and process for the preparation thereof | SAMJIN PHARMACEUTICAL CO., LTD. (KR) | 2005-10-06 | — | — | US | disclosed |
| EP-1487799-A4 | 9-AMINOACRIDINE DERIVATIVES AND PROCESS FOR THE PREPARATION THEREOF | SAMJIN PHARM CO LTD (KR) | 2005-06-01 | — | — | EP | disclosed |
| CN-1622939-A | 9-aminoacridine derivatives and process for the preparation thereof | SAMJIN PHARM CO LTD (KR) | 2005-06-01 | — | — | CN | disclosed |
| EP-1487799-A1 | 9-AMINOACRIDINE DERIVATIVES AND PROCESS FOR THE PREPARATION THEREOF | Samjin Pharmaceutical Co., Ltd. (KR) | 2004-12-22 | — | — | EP | disclosed |
| WO-2003074490-A1 | 9-AMINOACRIDINE DERIVATIVES AND PROCESS FOR THE PREPARATION THEREOF | SAMJIN PHARMACEUTICAL CO., LTD. (KR) | 2003-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230121721-A1 | MONOACYLGLYCEROL LIPASE INHIBITORS | MGLL, PNLIP, LIPA | SMN1; SMN2 3452/4885HTT 4475/4885SCD 93/4885 |
| US-20050222167-A1 | 9-aminoacridine derivatives and process for the preparation thereof | PARP9, CASP9, AMPD2 | SMN1; SMN2 2627/4885HTT 2920/4885SCD 4418/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.